| Company Name: |
Jilin Chinese Academy of Sciences-yanshen Technology |
| Tel: |
+undefined18143011203 |
| Email: |
info@chemextension.com |
| Products Intro: |
Product Name:1-Hydroxy-3,6,9,12,15,18,21,24,27,30-decaoxatritriacontan-33-oic acid
CAS:2375611-66-6
Purity:95%+ Package:1g;5g;10g;25g;50g;100g; Remarks:accept Custom Synthesis Services, support large packing
|
|
|
|
|
| Company Name: |
Xi'an Confluore Biological Technology Co., Ltd.
|
| Tel: |
+86-156-80926068 +86-15680926068 |
| Email: |
1924344760@qq.com |
| Products Intro: |
Product Name:Hydroxy-PEG10-acid
CAS:2375611-66-6
Purity:98% HPLC Package:10MG;25MG;50MG;100MG;1G;5G Remarks:For customers outside China,please use the website:www.confluore.com
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Hydroxy-PEG10-acid
CAS:2375611-66-6
Purity:97% Package:1g;100g;1kg
|
HO-PEG10-CH2CH2COOH manufacturers
- Hydroxy-PEG10-acid
-
- $0.00 / 1g
-
2024-03-25
- CAS:2375611-66-6
- Min. Order: 1g
- Purity: >98.00%
- Supply Ability: 1g
|
| | HO-PEG10-CH2CH2COOH Basic information |
| Product Name: | HO-PEG10-CH2CH2COOH | | Synonyms: | HO-PEG10-CH2CH2COOH;PROTAC Linkers,ADC Linkers,Inhibitor,inhibit,Hydroxy PEG10 acid,Antibody-drug conjugates linkers,Hydroxy-PEG-10-acid,HydroxyPEG10acid;Propanoic acid, 3-[(29-hydroxy-3,6,9,12,15,18,21,24,27-nonaoxanonacos-1-yl)oxy]-;1-Hydroxy-3,6,9,12,15,18,21,24,27,30-decaoxatritriacontan-33-oic acid | | CAS: | 2375611-66-6 | | MF: | C23H46O13 | | MW: | 530.6 | | EINECS: | | | Product Categories: | | | Mol File: | 2375611-66-6.mol |  |
| | HO-PEG10-CH2CH2COOH Chemical Properties |
| Boiling point | 614.7±55.0 °C(Predicted) | | density | 1.143±0.06 g/cm3(Predicted) | | pka | 4.28±0.10(Predicted) |
| | HO-PEG10-CH2CH2COOH Usage And Synthesis |
| Biological Activity | Hydroxy-PEG10-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. | | References | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 |
| | HO-PEG10-CH2CH2COOH Preparation Products And Raw materials |
|